instmctions): The purpose of the proposed Mayo Clinic Ovarian SPORE is to sfimulate and facilitate rigorous translational research in ovarian cancer?work that will take new basic and population science discoveries and convert them to improved intervenfions for women with ovarian cancer. Three of the four projects in this SPORE grant rely heavily on this proposed Animal Models Core for the evaluafion of novel interventions (imaging and therapeufics) and for refining experimental approaches and delivery regimens in ovarian cancer-bearing mice. To ensure that all the animal experimentafion can be performed in an expert and efficient manner?, and that SPORE investigators use standarized models for their varying therapeutic strategies?the Animal Core will serve as a central resource and, in collaboration with the laboratory personnel from each project, will perform all the animal experimentafion described in the projects. Specifically, the Animal Core will: (1) ensure the efficient planning, piurchase and ufilizafion of experimental mice, (2) provide the necessary facilifies and animal handling expertise for the projects;(3) provide xenograft and immunocompetent mouse models for testing of novel agents and therapeutic strategies and (4) provide veterinary expertise and access to non-invasive imaging strategies to monitor tumor burden. Importantly, the Animal Models Core will assure the following: (1) Consistency in animal modeling. Modeling through this core will maintain consistency in methods and outcomes, making it easier to reproduce our findings and easier to combine approaches from other labs;(2) Provision of strong animal modeling expertise to all projects. While all project teams have had experience with animal models, some have less than others. By providing a core, we can ensure that all SPORE members will have access to the highest level of skills available;(3) Opfimal interaction across projects with regard to modeling strategies. The core will bring together the investigators from each project and provide an outstanding avenue for new collaborations and the strengthening of existing collaborafions; (4) Efficiency in animal use and care. This core will result in an organized approach to animal use, minimizing waste and the numbers of animals used and eliminafing redundancy in personnel.

Public Health Relevance

The Animal Models core will develop and maintain murine models of ovarian cancer. These models are necessary for understanding the complex interacfions of ovarian cancer with normal healthy tissues and the immune system. Further, the models are needed for the development of novel therapeutics that require animal tesfing prior to human clinical use.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Babic, Ana; Cramer, Daniel W; Kelemen, Linda E et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control 28:459-468
Li, Yunhui; Luo, Kuntian; Yin, Yujiao et al. (2017) USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response. Nat Commun 8:15752
Butler, Kristina A; Hou, Xiaonan; Becker, Marc A et al. (2017) Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia 19:628-636
Wang, Chen; Armasu, Sebastian M; Kalli, Kimberly R et al. (2017) Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. Clin Cancer Res 23:4077-4085
Ovarian Tumor Tissue Analysis (OTTA) Consortium (2017) Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol 3:e173290
Kar, Siddhartha P; Adler, Emily; Tyrer, Jonathan et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer 116:524-535
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Dicks, Ed; Song, Honglin; Ramus, Susan J et al. (2017) Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget 8:50930-50940
Nounamo, Bernice; Liem, Jason; Cannon, Martin et al. (2017) Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model. Mol Ther Oncolytics 6:90-99

Showing the most recent 10 out of 269 publications